Compare Invesco S&P 500 High Div Low Volatility ETF (SPHD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco S&P 500 High Div Low Volatility ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Invesco S&P 500 High Div Low Volatility ETF trades at $48.79 (market cap $3.14B), while State Street SPDR S&P Biotech ETF trades at $153.7 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 3.2× Invesco S&P 500 High Div Low Volatility ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Invesco S&P 500 High Div Low Volatility ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco S&P 500 High Div Low Volatility ETF for 125 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SPHD | XBI | |
|---|---|---|
Market Cap | $3.14B | $10.11B |
Volume | 1,461,349 | 12,903,266 |
52-Week High | $53.55 | $169.55 |
52-Week Low | $46.96 | $104.99 |
Typical Hold Time | 125 Days | 38 Days |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPHD trades at $48.82, up 1.31% today, but technical indicators show a bearish trend with 17 sell signals versus 4 buy signals. The ETF's moving averages are unanimously bearish while oscillators remain neutral. Recent dividend payments of $0.20 and $0.21 demonstrate its income focus, though financial ratios are unavailable in the current data.
The outlook remains cautious given the bearish technical picture and mixed sentiment. While SPHD offers monthly dividend convenience for income investors, concerns about total return performance versus peers like SCHD present risks. Market volatility and yield sustainability are key considerations for potential investors.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
